US health-AI companies building on platforms like Doximity understand US physician engagement at scale — what US doctors use, what workflows they adopt, what clinical AI features they trust. But US platform strength does not automatically translate to UK adoption. The UK healthcare market operates under different rules, different procurement pathways, different regulatory requirements, different clinical expectations, and different trust dynamics. Understanding what US physicians engage with tells you very little about what UK clinicians need, what the NHS will approve, or what the MHRA requires.
This is not a cultural nuance or a minor localisation challenge. It is a structural market-entry barrier that has caught many US health-AI companies unprepared — leading to delayed launches, failed NHS procurement bids, MHRA classification disputes, and products that UK clinicians do not trust because they were designed for a different healthcare system with different guidelines, different drug data, and different professional accountability expectations.
What Changes in the UK
Regulatory expectations. The MHRA assesses whether software — including AI — qualifies as a medical device based on intended use. US companies accustomed to FDA 510(k) or De Novo pathways face different classification criteria, different evidence expectations, different post-market surveillance requirements, and different relationships between intended-use claims and regulatory classification. Getting the intended-use statement wrong triggers regulatory exposure that is expensive, time-consuming, and reputation-damaging to remediate. MHRA classification is not an afterthought — it determines whether the product can legally be placed on the UK market.
Clinical safety standards. DCB 0129 (manufacturer) and DCB 0160 (deploying organisation) set clinical safety standards for health IT systems deployed in the NHS. These require systematic hazard identification, clinical risk management, documented clinical safety cases, and named Clinical Safety Officers. US companies that have not built clinical safety case methodology into their product development lifecycle face a significant process gap — and cannot simply write a safety case retrospectively for a product that was not designed with hazard analysis in mind.
DTAC assessment. The Digital Technology Assessment Criteria cover clinical safety, data protection, technical security, interoperability, and usability. DTAC is increasingly expected — often required — for NHS procurement. Without DTAC, many NHS procurement routes are effectively closed. The assessment is comprehensive and specific to UK requirements.
NHS procurement. UK health-system adoption involves institutional procurement decisions at Trust, ICB, or national level — requiring business cases, governance approval, IG assessment, clinical champion engagement, staff training plans, and sometimes formal tender processes. The US model of clinician-direct distribution (individual physician downloads the app) or consumer-direct distribution does not apply in most NHS contexts. Even "free" tools require governance assessment before deployment.
Guideline localisation. Clinical AI products must align with UK guidelines — NICE, CKS, SmPC/eMC, MHRA drug safety updates — not US guidelines. A product that provides ACC/AHA cardiovascular recommendations to UK GPs is not just less useful; it may be clinically inappropriate when UK NICE guideline thresholds differ. A product that cites FDA drug labels rather than UK SmPCs may reference different licensed indications, different doses, different contraindications, and different monitoring requirements.
Evidence and claims. UK advertising regulations (ASA, PAGB) and medical device regulations constrain what clinical AI companies can claim. Marketing language that works in the US — "AI-powered diagnosis," "clinically proven" without specific evidence, implied autonomous decision-making, or unqualified accuracy claims — may create regulatory exposure or mislead UK clinicians.
Clinician trust. UK clinicians operate within GMC/GPhC professional accountability frameworks. They are personally and professionally accountable for every clinical decision, regardless of what AI tools informed it. Trust in clinical AI is shaped by source provenance (where does the answer come from and can I check it?), governance transparency (is the tool regulated, safety-assessed, and governed?), and professional alignment (does it support my professional judgement rather than claiming to replace it?).
What iatroX Insights Can Provide
iatroX Insights supports international health-AI companies entering the UK market through a comprehensive, regulatory-aware market-entry service.
UK market-entry readiness reports. Assessment of regulatory, clinical safety, procurement, evidence, and guideline-alignment requirements — identifying gaps between the product's current state and UK market requirements, with remediation recommendations and realistic timeline estimates.
MHRA classification advisory. Analysis of whether the product's intended use triggers medical device classification, what the pathway requires, and what changes to intended-use statements or product positioning might affect classification.
DTAC and DCB 0129/0160 readiness. Gap analysis against Digital Technology Assessment Criteria and clinical safety standards, with specific remediation recommendations. CSO services for companies needing clinical safety case development, hazard logs, and clinical risk management documentation.
Claims review. Assessment of marketing and clinical claims against UK regulatory requirements — ensuring compliance before market launch.
Clinician validation sprints. Structured evaluation by UK clinicians — producing actionable feedback about accuracy, usability, trust, and workflow fit in the UK context.
Guideline localisation assessment. Identifying where clinical content needs UK-specific adaptation — which US guidelines need NICE/CKS equivalents, which drug data needs SmPC alignment, which clinical workflows need NHS contextualisation.
Aggregate query intelligence. Understanding what UK clinicians actually search for and need — informing product design based on real UK clinical behaviour rather than assumptions.
Use iatroX Insights to prepare a US health-AI product for UK clinical and regulatory reality →